|
|
 |
|
Viewing report
|
|
|
|
Tuberculosis Therapeutics - Global Strategic Business Report
Global Industry Analysts, Inc., April 2010, Pages: 366
This report analyzes the Global market for Tuberculosis Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 37 companies including AstraZeneca, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline Plc, Lupin Limited, Novartis AG, Ranbaxy Laboratories Limited, Rusan Pharma Ltd., Rx for Africa, Inc., Sanofi-Aventis SA, Summit Plc, Tibotec BVBA, Otsuka Pharmaceutical Co., Ltd., and Sequella, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Competitor Analysis: Tuberculosis Vaccines and Therapeutics
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life
Hepatitis C Virus and Therapeutics - Global Strategic Business Report
Osteoporosis Therapeutics - Global Strategic Business Report
Inflammatory Bowel Disease Therapeutics - Global Strategic Business Report
Sepsis Therapeutics - Global Strategic Business Report
Multiple Sclerosis Therapeutics - Global Strategic Business Report
Imaging Agents - Global Strategic Business Report
Alzheimers and Parkinsons Disease - Global Strategic Business Report
Organ and Tissue Transplantation - Global Strategic Business Report
|
|
|
|
